Renal Business Today

Anemia

DOPPS: EPO Doses Drop 15% in One Year

WASHINGTON—In the wake of a number of regulatory and payment changes in ESRD care, nephrologists are changing their behavior in anemia management. This is evident in the drop in prescribed epoetin doses and hemoglobin levels in dialysis patients, according to the latest ...More
5 weeks ago
Posted in News, Clinical & Pharma, Practice Management
Hospira Starts Phase 3 of Biosimilar EPO Study

LAKE FOREST, Ill.—Hospira said Jan. 10 that it has started enrollment of the first patient in a Phase 3 U.S. clinical program for its biosimilar erythropoietin (EPO). ...More
January 10, 2012
Posted in News, Clinical & Pharma
FDA Panel Votes in Favor of Affymax Anemia Drug

A federal panel has voted 15-1 in favor of recommending the FDA approval of Affymax's anemia drug peginesatide, according to a Dec. 7 report from the San Francisco Business Times. ...More
December 7, 2011
Posted in Blog, Clinical & Pharma, Government & Regulation
Amgen, DaVita Ink Epogen Deal Through 2018

THOUSAND OAKS, Calif.—DaVita signed on Nov. 15 a supply agreement with Amgen under which Epogen will account for at least 90 percent of the dialysis provider's anemia drug requirements through 2018, according to a Nov. 18 regulatory filing from Amgen. ...More
November 21, 2011
Posted in News, Business
CMS Raises Dialysis Reimbursement for 2012, Revises QIP

WASHINGTON—The Centers for Medicare & Medicaid Services (CMS) released a final rule Nov. 1 that increases dialysis reimbursement in 2012 and alters the quality incentive program (QIP) by removing the lower hemoglobin target for anemia management in 2013 and expands the ...More
November 2, 2011
Posted in News, Business, Government & Regulation, Practice Management
FDA to Review Peginesatide in December

PALO ALTO, Calif. –The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for Affymax’s peginesatide proposed for the treatment of anemia associated with chronic kidney disease (CKD) in adult ...More
October 24, 2011
Posted in News, Government & Regulation
2011 USRDS Report By the Numbers

The following slides highlight some of the major ESRD-related highlights from the latest USRDS report, which was released in mid-October. ...More
October 18, 2011
Posted in Galleries, Business, Clinical & Pharma, Government & Regulation, Practice Management
Average HgB Levels in Dialysis Patients Fell Slightly

WASHINGTON—In its first post-bundle analysis, the Dialysis Outcomes and Practice Patterns Study (DOPPS) found that the average hemoglobin levels in dialysis patients fell slightly between August 2010 and April 2011. ...More
September 27, 2011
Posted in News, Clinical & Pharma, Government & Regulation
Rockwell Names VP of Drug Development, Medical Affairs

WIXOM, Mich.—Rockwell Medical has hired Annamaria T. Kausz, MD, MS, to replace Dr. Richard Yocum as Vice President of Drug Development and Medical Affairs. ...More
September 19, 2011
Posted in News, Business
FibroGen Names VP of Technical Development

SAN FRANCISCO— FibroGen Inc. has named Michael Martinelli, PhD, as Vice President, Technical Development. ...More
September 12, 2011
Posted in News, Business